TTI:CA:TSV-Thiogenesis Therapeutics Corp. (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.81

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

9.48K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.09 (+4.46%)

USD 0.16B
ARCH:CA Arch Biopartners Inc

-0.12 (-5.94%)

USD 0.12B
MIR:CA MedMira Inc

N/A

USD 0.05B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

+0.18 (+18.56%)

USD 0.02B
CZO:CA Ceapro

+0.02 (+8.33%)

USD 0.02B
KNE:CA Kane Biotech Inc

-0.01 (-3.85%)

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

+0.45 (+12.43%)

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing TTI:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.00% 38% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.00% 38% F 63% D
Trailing 12 Months  
Capital Gain 52.83% 83% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.83% 83% B 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 18.22% 75% C 69% C-
Dividend Return 18.22% 75% C 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.36% 92% A 89% A-
Risk Adjusted Return 85.29% 96% N/A 100% F
Market Capitalization 0.03B 79% B- 80% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.